The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2025 | Insights into the QuANTUM-Wild trial
In this video, Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, shares insights into the Phase III QuANTUM-Wild trial (NCT06578247), which is evaluating quizartinib in combination with chemotherapy for patients with FLT3-ITD-negative acute myeloid leukemia (AML). This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Astellas, Takeda, Daiichi Sankyo, Pfizer, Syndax, Kura, Servier, BMS, Abbvie, Genentech, AstraZeneca, Autolus, TheromoFsher, Prelude, Schrodinger, Remix, Rigel, Genmab
